[go: up one dir, main page]

WO2024233875A3 - Composés hétérocycliques pour l'imagerie de tau agrégée dans des tauopathies - Google Patents

Composés hétérocycliques pour l'imagerie de tau agrégée dans des tauopathies Download PDF

Info

Publication number
WO2024233875A3
WO2024233875A3 PCT/US2024/028756 US2024028756W WO2024233875A3 WO 2024233875 A3 WO2024233875 A3 WO 2024233875A3 US 2024028756 W US2024028756 W US 2024028756W WO 2024233875 A3 WO2024233875 A3 WO 2024233875A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
heterocyclic compounds
tauopathies
aggregated tau
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/028756
Other languages
English (en)
Other versions
WO2024233875A2 (fr
Inventor
Chester A. Mathis, Jr.
Jeffrey S. STEHOUWER
Robert H. Mach
Thomas J. A. GRAHAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
University of Pittsburgh
Original Assignee
University of Pennsylvania Penn
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, University of Pittsburgh filed Critical University of Pennsylvania Penn
Priority to AU2024267789A priority Critical patent/AU2024267789A1/en
Publication of WO2024233875A2 publication Critical patent/WO2024233875A2/fr
Publication of WO2024233875A3 publication Critical patent/WO2024233875A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés hétérocycliques de formule I ou de formule II ou leurs sels, solvates, hydrates, tautomères ou stéréoisomères pharmaceutiquement acceptables pour l'imagerie d'agrégats de tau. Les composés de formule I ou de formule II peuvent être utilisés pour la détection d'agrégats de tau dans le diagnostic ou la surveillance de la progression d'une maladie ou d'un trouble tel que la maladie d'Alzheimer, la dégénérescence corticobasale et la paralysie supranucléaire progressive.
PCT/US2024/028756 2023-05-11 2024-05-10 Composés hétérocycliques pour l'imagerie de tau agrégée dans des tauopathies Pending WO2024233875A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024267789A AU2024267789A1 (en) 2023-05-11 2024-05-10 Heterocyclic compounds for imaging aggregated tau in tauopathies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363465817P 2023-05-11 2023-05-11
US63/465,817 2023-05-11

Publications (2)

Publication Number Publication Date
WO2024233875A2 WO2024233875A2 (fr) 2024-11-14
WO2024233875A3 true WO2024233875A3 (fr) 2025-04-03

Family

ID=93431146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/028756 Pending WO2024233875A2 (fr) 2023-05-11 2024-05-10 Composés hétérocycliques pour l'imagerie de tau agrégée dans des tauopathies

Country Status (2)

Country Link
AU (1) AU2024267789A1 (fr)
WO (1) WO2024233875A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001967A1 (en) * 2002-05-14 2004-01-01 Lightronik Technology Inc. Organic el device
US20040067949A1 (en) * 2000-05-11 2004-04-08 Roland Grandel Substituted indoles which are parp inhibitors
WO2011011722A1 (fr) * 2009-07-23 2011-01-27 Vanderbilt University Benzoimidazolesulfonamides substitués et indolesulfonamides substitués en tant que potentialisateurs de mglur4
US8748420B2 (en) * 2010-05-27 2014-06-10 Bayer Cropscience Ag Pyridinylcarboxylic acid derivatives as fungicides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067949A1 (en) * 2000-05-11 2004-04-08 Roland Grandel Substituted indoles which are parp inhibitors
US20040001967A1 (en) * 2002-05-14 2004-01-01 Lightronik Technology Inc. Organic el device
WO2011011722A1 (fr) * 2009-07-23 2011-01-27 Vanderbilt University Benzoimidazolesulfonamides substitués et indolesulfonamides substitués en tant que potentialisateurs de mglur4
US8748420B2 (en) * 2010-05-27 2014-06-10 Bayer Cropscience Ag Pyridinylcarboxylic acid derivatives as fungicides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem Compound 5 December 2007 (2007-12-05), "2-(4-piperidin-1-ylphenyl)-1H-indole ", XP093301078, Database accession no. 21301874 *

Also Published As

Publication number Publication date
AU2024267789A1 (en) 2025-11-13
WO2024233875A2 (fr) 2024-11-14

Similar Documents

Publication Publication Date Title
MX2020011959A (es) Compuestos de heteroarilo y usos de los mismos.
ECSP24026637A (es) Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona
CA2913634C (fr) Inhibiteurs de fibrose a petites molecules
WO2006125101A3 (fr) Composes inhibiteurs raf et procedes d'utilisation de ceux-ci
WO2007027855A3 (fr) Composes inhibiteurs de la raf kinase et procedes d'utilisation de ceux-ci
EP1802588A1 (fr) Amino-pyrimidones substitues et utilisation de ceux-ci
FI3689865T3 (fi) Uusia aminopyrimidiinijohdannaisia
WO2008044243A3 (fr) Nouveau procédé de préparation de statines et leurs sels pharmaceutiquement acceptables
BRPI0410653A (pt) composto, composição farmacêutica, e, uso de um composto ou um sal, solvato, hidrato ou n-óxido farmaceuticamente aceitável do mesmo
CA2417106A1 (fr) Derives de la piperazine
CA2472954A1 (fr) Aza-arylpiperazines
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
CA2404464A1 (fr) Derives de la pyrrolidine et de la piperidine et leur utilisation pour le traitement de maladies neurodegeneratives
WO2007143523A8 (fr) Sulfonamides tricycliques condensés inhibiteurs de gamma-secrétase
CR20200326A (es) Derivados de 1,3,4, 5-tetrahidro-2h-pirido[4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tal como la enfermedad de alzheimer.
PH12021552760A1 (en) 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
WO2007064553A3 (fr) Derives de thiazole comme modulateurs de recepteurs cxcr3
JP2019519586A5 (fr)
JP2007502808A (ja) 哺乳類における依存症の予防と治療のための薬剤組成物
WO2007054770A3 (fr) Composes utiles en therapie
WO2024233875A3 (fr) Composés hétérocycliques pour l'imagerie de tau agrégée dans des tauopathies
NO20004668L (no) 1-(3-heteroarylpropyl- eller -prop-2-enyl)-4- benzylpiperidiner anvendt som NMDA-reseptorantagonister
CA3004095A1 (fr) Inhibiteurs d'arginine gingipaine
GEP20237534B (en) Spirochromane derivatives
TW200704633A (en) Process for the preparation of sulfonamide derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24804318

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024267789

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024267789

Country of ref document: AU

Date of ref document: 20240510

Kind code of ref document: A